Intravenous Octreotide Dosage
For acute variceal hemorrhage in cirrhosis, administer octreotide as an initial IV bolus of 50 mcg (which can be repeated in the first hour if bleeding continues), followed by continuous IV infusion of 50 mcg/hour for 2-5 days. 1
Variceal Hemorrhage (Primary Indication)
This is the most common and critical indication for IV octreotide in acute care settings. The dosing is standardized across major hepatology guidelines:
- Initial bolus: 50 mcg IV (can repeat within first hour if ongoing bleeding)
- Maintenance infusion: 50 mcg/hour continuous IV
- Duration: 2-5 days 1, 2
The 2018 EASL guidelines and 2017 AASLD guidelines both confirm this regimen reduces 7-day all-cause mortality and transfusion requirements 1. Start octreotide immediately when variceal hemorrhage is suspected—before diagnostic endoscopy is performed 2. This early initiation is critical for mortality reduction.
Duration Considerations
- Standard duration: 5 days to prevent early rebleeding 2
- Shorter duration (48-72 hours): May be considered in less severe episodes (Child-Pugh A/B with no active bleeding at endoscopy), though more data are needed 2, 3
- The 2024 AGA expert review suggests 2-day treatment may be reasonable only in highly selected Child-Pugh A/B patients without active bleeding at endoscopy 3
Important Clinical Points
Octreotide is the only vasoactive drug available in the United States for this indication 1. While terlipressin and somatostatin are alternatives used internationally, octreotide has the best safety profile with significantly fewer adverse events (2.39-fold lower risk compared to terlipressin/vasopressin) 3.
The bolus can be repeated if bleeding is ongoing, and additional boluses may be given during the treatment course if rebleeding occurs 2.
Other Indications (Per FDA Label)
Acromegaly
- Initial dose: 50 mcg IV 2-3 times daily
- Titration: Increase to 100 mcg 3 times daily (most common effective dose)
- Maximum: Up to 500 mcg 3 times daily, though doses >300 mcg/day rarely provide additional benefit 4
Carcinoid Tumors
- Initial 2 weeks: 100-600 mcg/day in 2-4 divided doses (mean 300 mcg/day)
- Maintenance: Median 450 mcg/day; range 50-1500 mcg/day 4
VIPomas
- Initial 2 weeks: 200-300 mcg/day in 2-4 divided doses
- Usual maximum: 450 mcg/day 4
Administration Details
- IV push: Can be given over 3 minutes
- IV infusion: Dilute in 50-200 mL of sterile isotonic saline or D5W and infuse over 15-30 minutes
- Emergency situations (e.g., carcinoid crisis): May be given by rapid bolus 4
- Stability: Stable in saline or D5W for 24 hours 4
Critical Safety Information
Do not mix octreotide in Total Parenteral Nutrition (TPN) solutions—it forms a glycosyl octreotide conjugate that decreases efficacy 4.
Common Pitfalls to Avoid
- Delaying initiation: Start octreotide as soon as variceal bleeding is suspected, not after endoscopy confirmation
- Stopping too early: Continue for full 2-5 days even after bleeding control to prevent early rebleeding
- Forgetting the bolus: The initial 50 mcg bolus is essential; don't start with infusion alone
- Wrong indication: Recent evidence shows octreotide is ineffective for intraoperative carcinoid crisis—vasopressors should be first-line treatment instead 5
Adverse Effects
Generally well-tolerated. May cause hypoglycemia or hyperglycemia (adjust insulin accordingly), bradycardia, and rarely pancreatitis 6. The safety profile is superior to vasopressin analogues, with minimal cardiovascular complications 3.